144 related articles for article (PubMed ID: 18536971)
1. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer.
Lee CT; Chow NH; Su PF; Lin SC; Lin PC; Lee JC
Dis Colon Rectum; 2008 Aug; 51(8):1268-74. PubMed ID: 18536971
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.
Watanabe H; Yokoyama Y; Kokuryo T; Ebata T; Igami T; Sugawara G; Mizuno T; Shimoyama Y; Nagino M
Ann Surg Oncol; 2015 Jul; 22(7):2235-42. PubMed ID: 25586241
[TBL] [Abstract][Full Text] [Related]
4. The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma.
Hayashi Y; Yamaguchi J; Kokuryo T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Nagino M
Anticancer Res; 2016 Dec; 36(12):6585-6592. PubMed ID: 27919987
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract.
Compérat E; Roupret M; Chartier-Kastler E; Bitker MO; Richard F; Camparo P; Capron F; Cussenot O
J Urol; 2008 Mar; 179(3):868-72; discussion 872. PubMed ID: 18221954
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
Lee WY; Chen HH; Chow NH; Su WC; Lin PW; Guo HR
Clin Cancer Res; 2005 Mar; 11(6):2222-8. PubMed ID: 15788670
[TBL] [Abstract][Full Text] [Related]
8. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
[TBL] [Abstract][Full Text] [Related]
9. MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting.
Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
Pathol Res Pract; 2014 Aug; 210(8):494-500. PubMed ID: 24814255
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.
Wang SL; Weng DF; Wei HX; Huang Z; Lin RQ; Shi K; Lin JH
J Orthop Sci; 2021 Nov; 26(6):1100-1106. PubMed ID: 32972820
[TBL] [Abstract][Full Text] [Related]
11. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients.
Ferrandina G; Martinelli E; Petrillo M; Prisco MG; Zucconi A; Santaguida S; Zannoni G; Scambia G; Ferlini C
Gynecol Oncol; 2008 Nov; 111(2):237-43. PubMed ID: 18718649
[TBL] [Abstract][Full Text] [Related]
13. Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis.
Park YL; Lee GH; Kim KY; Myung E; Kim JS; Myung DS; Park KJ; Cho SB; Lee WS; Jung YD; Kim HS; Joo YE
Tumori; 2012; 98(5):652-62. PubMed ID: 23235762
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
Zhou YQ; He C; Chen YQ; Wang D; Wang MH
Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
[TBL] [Abstract][Full Text] [Related]
16. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis.
Zhuang XP; Jin WW; Teng XD; Yuan ZZ; Lin QQ; Xu ST
Eur J Gynaecol Oncol; 2015; 36(3):255-9. PubMed ID: 26189249
[TBL] [Abstract][Full Text] [Related]
17. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
18. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
19. Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Liu YZ; Han DT; Shi DR; Hong B; Qian Y; Wu ZG; Yao SH; Tang TM; Wang MH; Xu XM; Yao HP
World J Gastrointest Oncol; 2020 Nov; 12(11):1216-1236. PubMed ID: 33250957
[TBL] [Abstract][Full Text] [Related]
20. Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.
Yoon TM; Kim SA; Park YL; Lee KH; Sung MW; Lee JK; Lim SC; Chung IJ; Joo YE
Head Neck; 2013 Aug; 35(8):1106-13. PubMed ID: 22887469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
